Docetaxel Stocks List

Recent Signals

Date Stock Signal Type
2021-05-07 ATNX Crossed Above 50 DMA Bullish
2021-05-07 BYSI 20 DMA Resistance Bearish
2021-05-07 BYSI NR7 Range Contraction
2021-05-07 BYSI Narrow Range Bar Range Contraction
2021-05-07 INFI Crossed Above 20 DMA Bullish
2021-05-07 INFI Bollinger Band Squeeze Range Contraction
2021-05-07 PSTV Fell Below 20 DMA Bearish
2021-05-07 PSTV Calm After Storm Range Contraction

Recent News for Docetaxel Stocks

Date Stock Title
May 8 ATNX Athenex, Inc. (ATNX) CEO Johnson Lau on Q1 2021 Results - Earnings Call Transcript
May 7 ATNX Athenex, Inc. (ATNX) Q1 2021 Earnings Call Transcript
May 6 ATNX Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates
May 6 ATNX Athenex: Q1 Earnings Insights
May 6 INFI Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast
May 6 ATNX Athenex EPS beats by $0.13, beats on revenue
May 6 ATNX Athenex Provides First Quarter 2021 Corporate and Financial Update
May 6 ATNX Athenex, Inc. to Host Earnings Call
May 5 ATNX Why Athenex Stock Skyrocketed Today
May 5 ATNX Why Athenex's Stock Is Trading Higher Today
May 5 ATNX 5 Top Stock Gainers for Wednesday: Under Armour, Match, Athenex
May 5 INFI Infinity to Present at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021
May 5 ATNX Athenex Snaps Up Kuur Therapeutics For $185M; Street Sees 133.7% Upside
May 5 ATNX Athenex Shares Gain After Acquiring Kuur Therapeutics For $70M Cash, $115M Milestone Payments
May 5 ATNX Athenex Jumps on Plan to Buy Cancer-Therapy Developer Kuur
May 4 ATNX Athenex to acquire Kuur Therapeutics in $185M deal
May 4 ATNX Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
May 4 PSTV Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract
May 4 PSTV Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements
May 3 INFI Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Related Industries: Biotechnology

Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.Common side effects include hair loss, low blood cell counts, numbness, shortness of breath, vomiting, and muscle pains. Other severe side effects include allergic reactions and future cancers. Side effects are more common in people with liver problems. Use during pregnancy may harm the baby. Docetaxel is in the taxane family of medications. It works by disrupting the normal function of microtubules and thereby stopping cell division.Docetaxel was patented in 1986 and approved for medical use in 1995. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Docetaxel is available as a generic medication. The wholesale cost in the developing world is about US$15.53 to US$87.37 per 80 mg vial. This dose in the United Kingdom costs the NHS about £454.53.

More about Docetaxel
Browse All Tags